StreetAlpha.app
Home › Stocks › FEMY

Femasys Inc (FEMY)

$1.24
▼ −1.59%
LAST CLOSE · NOV 20

Femasys makes women's health devices and diagnostics for fertility and permanent birth control, sold mainly to gynecologists and clinics. It last closed at $1.24 on Nov 20, down 1.59% on the day. The next earnings report for FEMY is expected around Tue, Mar 30, 2027, after the close. For the quarter ended Sep 2026, FEMY reported EPS of -$0.53 on revenue of $404,597, with revenue down 44.5% from a year ago. Over its last 8 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months FEMY insiders bought $134K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is FEMY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold FEMY.

Key Stats

Last 12 months
Results
Revenue
$2.0M
−4.2% vs a year ago
Net income
−$12.1M
−614.7% margin
Free cash flow
−$17.3M
−877.5% margin
Gross margin
59.9%
$1.2M gross profit
Valuation
Market cap
$10.7M
8.7M shares
P/E
–
Price to sales
5.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$23.9M
At Sep 30
Shareholder equity
$27.0M
Shares outstanding
8.7M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.2M$1.2MFY2021FY2022: $1.2M$1.2MFY2022FY2023: $1.1M$1.1MFY2023FY2024: $1.6M$1.6MFY2024FY2025: $2.3M$2.3MFY2025

From FEMY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 30
Estimated date · After the close
Reported EPS
-$0.53
Quarter ended Sep 2026
Year ago EPS
-$2.05
Same quarter last year
Revenue
$404,597
−44.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.23Dec '24Mar 2025: -$0.23Mar '25Jun 2025: -$3.18Jun '25Sep 2025: -$2.05Sep '25Dec 2025: $8.78Dec '25Mar 2026: $0.00Mar '26Jun 2026: -$1.33Jun '26Sep 2026: -$0.53Sep '26Latest -$0.53
Revenue by quarter
Dec 2024: $581,576Dec '24Mar 2025: $341,264Mar '25Jun 2025: $409,268Jun '25Sep 2025: $729,394Sep '25Dec 2025: $813,387Dec '25Mar 2026: $424,889Mar '26Jun 2026: $331,827Jun '26Sep 2026: $404,597Sep '26Latest $404,597
How FEMY moved after its last 8 reports
Average move the session after a report ±8.3%
Nov 13, 2026After the close−9.9%
Aug 14, 2026After the close−5.7%
May 8, 2026After the close−6.0%
Mar 31, 2026After the close−0.8%
Nov 14, 2025After the close−11.3%
Aug 8, 2025After the close−13.2%
May 8, 2025After the close−7.8%
Mar 27, 2025Time not announced−12.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on FEMYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on FEMY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on FEMY

Technical Analysis

FEMY · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 9% below its 20 day and 45% below its 50 day average. It is 332% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38), near oversold. The nearest support is the Pivot S1 at $1.20, and the nearest resistance the Pivot at $1.25.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityNormal, 12.3%/day
Key levels
$20.8052 week high+1577.4%
$5.35200 day average+331.5%
$2.44100 day average+96.8%
$1.8050 day average+45.2%
$1.53Swing high (Nov 4)+23.4%
$1.3520 day average+8.9%
$1.30Pivot R1+4.8%
$1.25Pivot+0.8%
$1.24Last close
$1.20Pivot S1−3.2%
$1.0752 week low−13.7%
$1.07Swing low (Nov 17)−13.7%
Indicators
RSI (14)37.55Weak, oversold below 30Neutral
MACD-0.16Above its signal lineBullish
Stochastic30.6Middle of its rangeNeutral
ADX (14)47.3Strong downtrend
Williams %R-64.6Oversold below −80, overbought above −20Neutral
CCI (20)-96.7Oversold below −100, overbought above 100Neutral
Rate of change−9.5%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FEMY

What happened before

See how FEMY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow FEMY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How FEMY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for FEMYHow many large options trades hit FEMY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

FEMY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲16 buying vs 9 selling
  • ▲Held by funds +52.0 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2820+40.0%
In funds' top 10110.0%
Held by funds75.9%23.9%+52.0 pts
New / increased12 / 418 / 0−11.1%
Reduced / sold out5 / 41 / 34−74.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FEMY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

FEMY Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$134K5 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 5 insiders bought $134K between Aug 7 and Aug 7.
2026-08 bought $134KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 7Kathy Lee-SepsickCEOBuy15,625$3.20$50K
Aug 7Dov ElefantCFOBuy15,625$3.20$50K
Aug 7John Charles CanningCOOBuy4,375$3.20$14K
Aug 7Jeremy Alexander SiposChief Technology OfficerBuy3,125$3.20$10K
Aug 7Jeffrey Gerald MifekChief Clinical-Medical AffairsBuy3,125$3.20$10K
Every insider buy and sale for FEMY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See FEMY insider trades →

From SEC Form 4 filings by FEMY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FEMY is in one of them and how their past FEMY trades turned out.

FEMY in the AI portfolios
Loading…

FEMY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FEMY in an article yet. Here's the latest on the wider market.

FEMY in the news

About Femasys

Femasys is a women's health company based in Suwanee, Georgia, that makes medical devices and diagnostic products. Its fertility products include FemaSeed, a treatment that places sperm directly into the fallopian tube, along with FemSperm sperm preparation kits and FemVue, an ultrasound test of the fallopian tubes. It also offers FemBloc, a permanent birth control option that does not require surgery, along with the FemChec and FemCath products. Its customers are gynecologists, fertility clinics and other healthcare practitioners who treat women and couples.

Headquarters
Suwanee, GA